Isotechnika chops staff, names acting CEO in restructuring

Canada's Aurinia Pharmaceuticals, formerly called Isotechnika, is shaking up its executive team and laying off staffers. The biotech says that Richard Glickman is now the acting CEO, replacing Robert Foster, who will take the CSO's job. About a third of the company's staff is being axed while it reduces the size of its offices by half. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.